Celldex Therapeutics (CLDX)

• Market cap: $1.21B
• 1 day: 2.81%
• 5 days: 14.45%
• 1 month: -10.07%
• 3 months: -23.04%
• 6 months: -36.33%
• Year to date: -29.04%
• 1 year: -53.82%
• 5 years: 810.45%
• 10 years: -95.44%
• Sector: Healthcare
• Industry: Biotechnology

About: Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Employees: 186

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

46% more call options, than puts

Call options by funds: $24.9M | Put options by funds: $17.1M

38% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 48

2.75% more ownership

Funds ownership: 108.33% [Q3] → 111.07% (+2.75%) [Q4]

6% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 36

1% less funds holding

Funds holding: 176 [Q3] → 174 (-2) [Q4]

24% less capital invested

Capital invested by funds: $2.44B [Q3] → $1.86B (-$579M) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $36 97% upside
• Avg. target: $55 198% upside
• High target: $80 337% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

Morgan Stanley Judah Frommer 40% 1-year accuracy 4 / 10 met price target	151% upside $46	Overweight Initiated	20 Mar 2025
Goldman Sachs Richard Law 50% 1-year accuracy 4 / 8 met price target	97% upside $36	Neutral Maintained	3 Mar 2025
HC Wainwright & Co. Joseph Pantginis 15% 1-year accuracy 62 / 415 met price target	337% upside $80	Buy Reiterated	3 Mar 2025
UBS Trung Huynh 13% 1-year accuracy 1 / 8 met price target	140% upside $44	Buy Initiated	13 Feb 2025
Cantor Fitzgerald Kristen Kluska 24% 1-year accuracy 24 / 102 met price target	266% upside $67	Overweight Reiterated	29 Jan 2025